Mpex pockets $32M in second venture round

San Diego-based Mpex Pharmaceuticals has raised $32 million in its second round of venture capital. The round was led by SV Life Sciences. The biotech's most advanced candidate is an aerosol antibacterial being developed to treat patients with cystic fibrosis and those with other serious respiratory infections. "This capital will enable us to advance our first two candidates through preclinical and early clinical development, as well as attract and support future R&D partnerships," said Mpex President and CEO Bill Gerhart.

- read this press release for more

ALSO: Germany's Avontec has raised $18 million in its second round. Release

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.